Patents Examined by Bong-Sook Baek
  • Patent number: 10254272
    Abstract: The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 9, 2019
    Assignee: Global Genomics Group, LLC
    Inventors: Szilard Voros, Bradley O. Brown, Idean B. Marvasty
  • Patent number: 10226423
    Abstract: The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 12, 2019
    Assignee: RxOMEG Therapeutics LLC
    Inventors: Indu Muni, Naomi Vishnupad
  • Patent number: 10213438
    Abstract: Alkaloid compounds described herein are useful for treating disorders associated with monoamine oxidase (MAO) activity, such as depression, pain, smoking cessation, and substance addictions, and/or for treating disorders associated with chronic or low-level inflammation. In some examples, compounds are effective for treating cancers, autoimmune disorders, and other disorders associated with inducible nitric oxide synthase (iNOS).
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 26, 2019
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 10208035
    Abstract: A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is N, C(OH), or CH; Y is H or OH; each of Z1-Z5 is independently H or halogen; R4 is H, OH, NH2, NHR8, NR8R9 or R8; R5, R6, and R7 is each independently H, halogen, OR8, R8, NHR8, NR8R9, CO2R8, CONR8R9, SO2NR8R9, or R5 and R6 together with the carbon atoms to which R5 and R6 are attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; and R8 and R9 is each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or R8 and R9 together with the nitrogen t
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 19, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xue Zhi Zhao, Steven Smith, Mathieu Metifiot, Barry Johnson, Christophe Marchand, Stephen H. Hughes, Yves Pommier, Terrence R. Burke, Jr.
  • Patent number: 10195190
    Abstract: Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Henry Brem, Antonella Mangraviti, Alessandro Olivi, Betty M. Tyler, Tula Raghavan
  • Patent number: 10188645
    Abstract: The disclosure is directed to a method of easing a patient's symptoms related to termination of opioid pain therapy, and compositions for achieving said method. The method and compositions comprise a series of self tapering dosages of a pharmaceutical composition that is configured to alleviate or prevent symptoms of the patient's termination of opioid pain therapy. The series of self tapering dosages may be supplied in a dosage package.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 29, 2019
    Inventors: Ian Cain Smith, Robert W. Mooney
  • Patent number: 10183032
    Abstract: The present disclosure relates to molecules that function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 22, 2019
    Assignees: Ball State Innovation Corporation, STC.UNM
    Inventors: Susan A. McDowell, Robert E. Sammelson, Larry A. Sklar, Mark K. Haynes
  • Patent number: 10179147
    Abstract: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: January 15, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Siam Oottamasathein, Thomas P. Kennedy
  • Patent number: 10172941
    Abstract: A process for synthesis of silica coated graphene hybrid material comprising the steps of treating graphene oxide with ammonium ions to provide ammonium-activated graphene oxide; treating the ammonium-activated graphene oxide with a solution comprising silica precursors; and silane coupling agents that comprise functional groups, to provide self-assembly of silica nanoparticles on the surface of the ammonium-activated graphene oxide and covalent bonding between the nanoparticles and the surface to provide silica coated graphene oxide; and grafting of the functional groups on the surface of the silica coated graphene oxide to provide functionalized silica coated graphene oxide; and reducing the functionalized silica coated graphene oxide to provide functionalized silica coated graphene. Silica coated graphene hybrid material obtainable by this process.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 8, 2019
    Assignee: SHT SMART HIGH-TECH AB
    Inventor: Johan Liu
  • Patent number: 10165791
    Abstract: The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular Rubus suavissimus extracts, for masking, reducing or suppressing a bitter, sour and/or astringent taste impression. The invention further relates to orally consumable preparations, comprising at least one bitter, sour and/or astringent-tasting substance and rubusoside or certain rubusoside-containing mixtures, preferably certain Rubus suavissimus extracts, a corresponding method of producing said preparations and a method for reducing or suppressing the bitter, sour and/or astringent effect of a bitter, sour and/or astringent-tasting substance. The invention further relates to certain flavoring compositions that are particularly effective for masking, reducing or suppressing a bitter, sour and/or astringent taste impression.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: January 1, 2019
    Assignee: Symrise AG
    Inventors: Jakob Peter Ley, Katharina Reichelt, Thomas Riess, Kathrin Langer, Susanne Paetz
  • Patent number: 10167263
    Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: January 1, 2019
    Assignees: NORTHWESTERN UNIVERSITY, CAMBRIA PHARMACEUTICALS, INC.
    Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanites, Richard I. Morimoto, Tian Chen, Richard B. Silverman
  • Patent number: 10155767
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 18, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Han Na Cho, Eun Hye Ju, Woo Young Hur, Ho Jong Yoon, Chi Man Song
  • Patent number: 10150787
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: December 11, 2018
    Inventors: Michel L. Tremblay, Claudia Penafuerte, Matthew Feldhammer, George Zogopoulos, Cameron Black, Brian Kennedy
  • Patent number: 10143693
    Abstract: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: December 4, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Srihari Gopal, Paulien Gerarda Maria Ravenstijn, Alberto Russu, Mahesh Narain Samtani
  • Patent number: 10123997
    Abstract: A method of treating hepatitis B virus includes inhibiting the activities of AKT and/or mTOR, inhibiting the synthesis of 5-phosphate ribose, and inhibiting HBV DNA and HBV cccDNA.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 13, 2018
    Inventor: Yong Liao
  • Patent number: 10117820
    Abstract: Provided is a cosmetic composition superior in antiseptic property and having high moisturizing property. A cosmetic composition containing (A) particular acylproline or a salt thereof, and (B) particular hydroxamic acid derivative, particular acetophenone derivative or diol compound.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: November 6, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Nana Haraya, Takanori Sugimoto, Takuya Okada
  • Patent number: 10105327
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 23, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10106619
    Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 23, 2018
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Michael Croft, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware
  • Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Patent number: 10092493
    Abstract: The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: October 9, 2018
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Jeong Ki Kim, Hyun Jung Shin, Su Nam Kim, Byeong Gon Lee, Ih Seop Chang